Impact of Anti-Giardia and Antihelmintic Treatment on Infant Growth in Bangladesh

University of Cambridge

Status: Completed

Conditions: Giardiasis

Treatments: Drug: Anti-Giardia treatment only (secnidazole or albendazole); Drug: Anti-Giardia and antihelmintic treatment (secnidazole or albendazole); Drug: Control group (placebo)

Study type: Interventional

Funder types: Other

Identifiers

NCT00607074

BMRC/ERC/2001-2004/2281

Details and patient eligibility

About

This longitudinal study aimed to assess whether regular anti-Giardia and antihelmintic treatment improved growth and small intestinal mucosal function of rural Bangladeshi infants.

Full description

A randomised double-blind controlled intervention of 36 weeks duration was conducted in a rural community located 40kms north-west of Dhaka, the capital of Bangladesh. Infants aged between 3 and 11 months were randomly assigned to either receiving anti-Giardia and antihelmintic treatment, or anti-Giardia treatment only, or a control group receiving placebos. Weight and supine length were recorded every 4 weeks. Every 12 weeks intestinal permeability (L/M ratio), haemoglobin, plasma albumin, alpha-1-acid glycoprotein, immunoglobulin G and Giardia intestinalis specific IgM titre (GSIgM) and eggs of the three common geohelminths and Giardia intestinalis cysts were determined.

Enrollment: 410 patients

Sex: All

Ages: 3 to 15 months old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• infants living in the study area

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

410 participants in 1 patient group

1

Experimental group

Treatment:

Drug: Control group (placebo)

Drug: Anti-Giardia treatment only (secnidazole or albendazole)

Drug: Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)